• SPX
  • $5,782.76
  • 1.23 %
  • $70.07
  • DJI
  • $42,221.88
  • 1.02 %
  • $427.28
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,172.39
  • -0.14 %
  • -$11.85
  • IXIC
  • $18,439.17
  • 1.43 %
  • $259.19
PureTech Health plc (PRTC) Stock Price, News & Analysis

PureTech Health plc (PRTC) Stock Price, News & Analysis

Currency in USD Disclaimer

$20.83

-$0.27

(-1.28%)

Day's range
$20.83
Day's range
$21
50-day range
$19.02
Day's range
$25
  • Country: US
  • ISIN: US7462371060
52 wk range
$17.08
Day's range
$34
  • CEO: Dr. Bharatt M. Chowrira J.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.74
  • Piotroski Score 1.00
  • Grade Overweight
  • Symbol (PRTC)
  • Company PureTech Health plc
  • Price $20.83
  • Changes Percentage (-1.28%)
  • Change -$0.27
  • Day Low $20.83
  • Day High $21.00
  • Year High $34.00

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 04/23/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $57.00
  • High Stock Price Target $70.00
  • Low Stock Price Target $44.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.40
  • Trailing P/E Ratio -12.47
  • Forward P/E Ratio -12.47
  • P/E Growth -12.47
  • Net Income $-65,697,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.